Skip to content

Examination of effectiveness of combination therapy of periodontal tissue regeneration drug Regroth and bone substitute material for periodontal tissue regeneration

Examination of effectiveness of combination therapy of periodontal tissue regeneration drug Regroth and bone substitute material for periodontal tissue regeneration - Study on combination therapy of Regroth and bone substitute material for periodontal tissue regeneration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000034480
Enrollment
80
Registered
2018-12-01
Start date
2018-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Disease

Interventions

Application of Regroth only at periodontal surgical treatment Combination therapy of Regroth and bone substitute material at periodontal surgical treatment

Sponsors

Tokushima University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Periodontal pocket depth of 4 mm or more, and vertical bone defect of 3 mm or more

Exclusion criteria

Exclusion criteria: Patients with severe systemic disease Patients who may be pregnant or pregnant Patients with mental illness Patients with hypersensitivity to "Regroth" Patient with malignant tumor in oral cavity or patient with an its history Case of predicted not to able to complete closure of the wound surface when filling with substitute bone material Tooth for severe periodontal disease and tooth extraction adapted tooth

Design outcomes

Primary

MeasureTime frame
Increase in new alveolar bone at 9 months after periodontal surgery

Countries

Japan

Contacts

Public ContactHiromichi Yumoto

Tokushima University Graduate School Department of Periodontology and Endodontology

yumoto@tokushima-u.ac.jp088-633-7343

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026